Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_assertion type Assertion NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_head.
- NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_assertion wasGeneratedBy ECO_0000203 NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_provenance.
- NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_assertion wasDerivedFrom befree-20150227 NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_provenance.
- NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_assertion SIO_000772 17992582 NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_provenance.
- NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_assertion evidence source_evidence_literature NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_provenance.
- NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_assertion description "[Ultimately, molecularly based designer pharmaceuticals may emerge from this research, such as the case of trastuzumab (Herceptin) in HER-2/neu positive breast cancer, and imatinib (Gleevec) in chronic myelocytic leukemia and gastrointestinal stromal tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379506.RABiI8bhrDO4aN31E1sAXYJb6lwnmSSaCetlb26QhWxO0130_provenance.